Connect Biopharma: DMC Recommends Continue Phase 2 Asthma/COPD Trials; Topline Data Mid-2026

Connect Biopharma Holdings Ltd

DMC reviewed pre-specified interim efficacy of rademikibart (anti-IL-4Rα) in Phase 2 Seabreeze STAT trials; no sample size change.
No treatment-related serious adverse events, no severe AEs, and no discontinuations due to AEs in either study.
Topline data from both asthma and COPD studies expected in mid-2026; company plans FDA meeting for Phase 3.
CEO Barry Quart: 'Rademikibart has potential to deliver differentiated efficacy and safety in acute exacerbations.'

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.